Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Molecular Analysis of Persistent and Recurrent Barrett's Esophagus in the Setting of Endoscopic Therapy
Kumar, Aarti , Rara, Marianne , Wen, Kwun Wah , Grady, William M., Chak, Amitabh , Iyer, Prasad G. , Rustgi, Anil K. , Rubenstein, Joel H. , Liu, Yue , Kresty, Laura A. , Westerhoff, Maria , Kwon, Richard S. , Wamsteker, Erik, Wang, Tom, Berry, Lynne D. , Shaheen, Nicholas J. , Wang, Kenneth K, Stachler, Matthew D , Yu, Ming , Wang, Timothy C. , Canto, Marcia Irene , Abrams, Julian A

Mayo Clinic

Clinical and Translational Gastroenterology | July 15, 2024 | Volume: 15 | Issue: 8 | Pages: e00751

10.14309/ctg.0000000000000751 | PMID 39007490 Get It

INTRODUCTION: Early neoplastic progression of Barrett's esophagus (BE) is often treated with endoscopic therapy. Although effective, some patients are refractory to therapy or recur after apparent eradication of the BE. The goal of this study was to determine whether genomic alterations within the treated BE may be associated with persistent or recurrent disease. METHODS: We performed DNA sequencing on pre-treatment esophageal samples from 45 patients who were successfully treated by endoscopic therapy and did not recur as well as pre-treatment and post-treatment samples from 40 patients who had persistent neoplasia and 21 patients who had recurrent neoplasia. The genomic alterations were compared between groups. RESULTS: The genomic landscape was similar between all groups. Patients with persistent disease were more likely to have pre-treatment alterations involving the receptor tyrosine kinase pathway ( P = 0.01), amplifications of oncogenes ( P = 0.01), and deletions of tumor suppressor genes ( P = 0.02). These associations were no longer significant after adjusting for patient age and BE length. More than half of patients with persistent (52.5%) or recurrent (57.2%) disease showed pre-treatment and post-treatment samples that shared at least 50% of their driver mutations. DISCUSSION: Pre-treatment samples were genomically similar between those who responded to endoscopic therapy and those who had persistent or recurrent disease, suggesting there is not a strong genomic component to treatment response. Although it was expected to find shared driver mutations in pre-treatment and post-treatment samples in patients with persistent disease, the finding that an equal number of patients with recurrent disease also showed this relation suggests that many recurrences represent undetected minimal residual disease.
Dopamine Dressing: AJR Podcast Series on Wellness, Episode 4
Wang, Sherry S.

Mayo Clinic

American Journal of Roentgenology | July 10, 2024 | Volume: 223 | Issue: 2 | Pages: No page available

10.2214/ajr.24.31697 | PMID 38984782 Get It

Updates in the Care of Women in Menopause
Wang, Annie Y., Files, Julia A. , Kransdorf, Lisa N , Kransdorf, Lisa N. , Wang, Annie Y.

Mayo Clinic

Journal of Women's Health | July 9, 2024 | Volume: 33 | Issue: 9 | Pages: 1283-1287

10.1089/jwh.2024.0644 | PMID 38979624 Get It

Fatty Infiltration, Tear Size, and Retraction Size Are Significant Risk Factors for Retear After Arthroscopic Rotator Cuff Repair: A Systematic Review
Darbandi, Azad J., Credille, Kevin , Darbandi, Aria , Hevesi, Mario , Dandu, Navya , Bodendorfer, Blake M. , Wang, Zachary , Garrigues, Grant E. , Verma, Nikhil N. , Yanke, Adam B. , Hevesi, Mario , Darbandi, Azad

Mayo Clinic

Arthroscopy | July 8, 2024 | Volume: 41 | Issue: 5 | Pages: 1649

10.1016/j.arthro.2024.06.040 | PMID 38986851 Get It

Purpose To assess the consistency and quality of risk factor reporting for rotator cuff repair (RCR) retear and identify risk factors most frequently associated with retear. Methods A systematic review was performed according to Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) guidelines. Of the initial 3,158 studies, a total of 31 met the following inclusion criteria: (1) clinical studies regarding RCR failure, (2) arthroscopic procedures involving RCR, (3) reporting of clinical outcomes, (4) publication within the past 5 years, and (5) studies investigating preoperative risk factors for retear. After full‐text review, 18 risk factors were analyzed. Results The most consistently significant risk factors were acromiohumeral distance (80%), critical shoulder angle (67%), tear size (63%), anterior‐posterior dimension (60%), fatty infiltration (FI) (58%), and retraction size (56%). FI was analyzed using different methods among studies, with 63% finding significant results and 50% of all studies performing ordinal analysis. Tear size was inconsistently analyzed quantitatively or qualitatively, with 58% of studies finding significant results and 63% of all studies performing quantitative analysis. Risk factors consistently found to be nonsignificant included age, sex, diabetes mellitus, symptom duration, hand dominance, repair technique, smoking, and body mass index. Conclusions Tear size, FI, and retraction size were found to be significant risk factors in most of the included studies evaluating rotator cuff retear. Risk factors less likely reported as predictive included repair technique, age, sex, diabetes mellitus, symptom duration, hand dominance, repair technique, smoking, and body mass index. Risk factors that require further investigation include critical shoulder angle, acromiohumeral distance, and anterior‐posterior tear dimension. Level of Evidence Level III, systematic review of Level III‐IV studies.
Baduanjin for ischemic heart failure with mildly reduced/preserved ejection fraction (BEAR Trial): A randomized controlled trial
Li, Jingen , Yu, Meili, Wang, Yanhui , Li, Siming , Li, Siwei , Feng, Xue , Li, R.K. , Chen, Keji , Xu, Hao , Li, Jingen , Li, Ruijie

Mayo Clinic

Journal of Evidence-Based Medicine | July 6, 2024 | Volume: 17 | Issue: 3 | Pages: 526-534

10.1111/jebm.12631 | PMID 38970325 Get It

AbstractAimWhile Baduanjin, a traditional Chinese mind‐body exercise, has shown potential health benefits, its efficacy in improving outcomes for heart failure patients with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) has not been well documented. We aimed to investigate the adjunctive impact of Baduanjin on exercise capacity and quality of life for HFmrEF/HFpEF.MethodsPatients with HFmrEF/HFpEF were enrolled in this multicenter randomized clinical trial. All participants were randomized to conventional cardiac rehabilitation with or without an additional 12‐week Baduanjin exercise. The primary endpoint was the distance covered in a 6‐min walk test (6MWD), while key secondary outcomes included quality of life measured by the Minnesota Living with Heart Failure Questionnaire (MLHFQ) and cardiopulmonary function including anaerobic threshold (VO2 AT).ResultsA total of 120 patients were enrolled, and 109 completed all session and tests. The mean age of the 120 patients was 60.5 years (SD, 9.21 years), and 23 (19.2%) were women. The Baduanjin group exhibited a 6.14% improvement in 6MWD compared to a 1.32% improvement in the control group (median improvement, 25.0 vs. 5.0 m; p < 0.001) at 12th week. The VO2 AT increased by 25.87% in the Baduanjin group versus 3.94% in the control group (p < 0.001). Quality of life also significantly improved in the Baduanjin group as indicated by MLHFQ score changes (–16.8% vs. –3.99%; p < 0.001).ConclusionsAdding Baduanjin to exercise‐based cardiac rehabilitation for patients with ischemic HFmrEF or HFpEF are generally safe and could provide significant improvements in exercise capacity and quality of life.
CareCompanion: A Personalized Virtual Assistant for Enhancing Support and Independence in ADRD Patients and Older Adults
Hasan, Wordh Ul , Zaman, Kimia Tuz , Shalan, Mohammed , Wang, Xin , Li, Juan , Xie, Bo , Tao, Cui

Mayo Clinic

2024 International Conference on Smart Applications, Communications and Networking (SmartNets) | July 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-10

10.1109/smartnets61466.2024.10577734 Get It

Micromagnetic Neural Stimulation and Spintronic Neural Sensing
Tonini, Denis , Hopper, Matthew S. , Goyal, Abhinav , Sanger, Zachary , Faramarzi, Sadegh , Shiao, Maple, Helden, Dusty Van , Wu, Kai , Keirstead, Susan A. , Netoff, Théoden I. , Low, Walter C. , Osborn, John, Bennet, Kevin E. , Lee, Kendall H. , Shin, Hojin , Wang, Jian-Ping , Saha, Renata , Yuen, Jason , Oh, Yoonbae , Bloom, Robert P. , Benally, Onri Jay

Mayo Clinic

2024 IEEE International Magnetic Conference - Short papers (INTERMAG Short papers) | July 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-2

10.1109/intermagshortpapers61879.2024.10576875 Get It

Comparative Evaluation of Candida Species-Specific T-Cell Immune Response in Human Peripheral Blood Mononuclear Cells
Pathakumari, Balaji , Liu, Weida, Wang, Qiong , Kong, Xue , Chokkakula, Santosh , Pathakamuri, Vasundhara, Nunna, Venkatrao , Liu, Weida , Liang, Guanzhao

Mayo Clinic

Biomedicines | July 5, 2024 | Volume: 12 | Issue: 7 | Pages: 1487

10.3390/biomedicines12071487 | PMID 39062060 Get It

Non-albicans Candida (NAC) species are increasingly recognized as significant contributors to candidemia infections; however, relatively less is known about the immune responses induced by these species. In this study, we compared the cytokine production ability of human peripheral blood mononuclear cells (PBMCs) upon stimulation with different Candida species (Candida spp.). We measured secreted cytokines using ELISA and checked the functional profiles of T-cell responses using multicolor flow cytometry. Although there was a differential expression of cytokines against Candida spp., significant difference were observed in the levels of IFN-γ, TNF-α, IL-10, IL-12p40, and IL-23 (p < 0.05) between Candida spp. A significant difference was observed between C. albicans and C. glabrata (p = 0.026) in the levels of TNF-α. C. glabrata showed significant differences compared to C. albicans, C. parapsilosis, and C. krusei in the levels of IL-10 (p values of 0.02, 0.04, and 0.01, respectively). Despite the percentages of CD4+ and CD8+ expressing Th1, Th2, and Th17 cytokines being higher in stimulated PBMCs, none of the Candida spp. showed significant differences. The levels of secreted IL-17A and IL-23 were consistently lower in Candida spp. regardless of the stimulus used. Here, we showed the differential regulation of Th1, Th2, and Th17 during Candida spp. stimulation of the immune system ex vivo. Additionally, our findings suggest that C. albicans elicits an IFN-γ response, whereas C. glabrata promotes IL-10 cellular responses, but this warrants additional studies to conclude this association. This investigation holds the potential to advance our comprehension of the distinct immune responses induced by Candida spp., with probable implications in designing antifungal immunotherapeutics.
CheMo4METPANC: A randomized phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) compared to chemotherapy alone in metastatic
Manji, Gulam A. , Chalabi, Morteza Hajkarim, Pellicciotta, Ilenia, Ana, Sarah Sta , Sender, Naomi , Pan, Samuel , Ross, Isabelle, Wang, Shikun , Izar, Benjamin , Wu, Linda, May, Michael S. , Labadie, Brian , Bates, Susan E. , Shi, Qian , Raufi, Alexander G.

Mayo Clinic

Journal of Clinical Oncology | July 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS4208-TPS4208

10.1200/jco.2024.42.16_suppl.tps4208 Get It

TPS4208 Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) carries a 5-year relative survival of 3%. Immune checkpoint inhibitors have thus far failed to improve outcomes due to an immunosuppressive tumor microenvironment (TME). Signaling through the C-X-C motif chemokine receptor 4 (CXCR4)/C-X-C motif chemokine ligand 12 (CXCL12) axis results in exclusion of anti-tumor immune cells in mouse PDAC models. Longitudinal survival studies testing combinations of CXCR4i, aPD-1, and gemcitabine in the KPC mouse model of PDAC demonstrated a survival benefit with the combination of all three agents. Results from a multicenter, investigator-initiated, single arm pilot study evaluating the preliminary safety and efficacy ofMotixafortide (CXCR4i), Cemiplimab (aPD1), Gemcitabine, and Nab-paclitaxel (MCGN) in 11 patients with treatment-naïve mPDAC were recently presented. Seven patients (64%) achieved a partial response, including 6 confirmed partial responses, and 10 patients (91%) had disease control, compared to historic partial response and disease control rates of 23% and 48%, respectively, with gemcitabine and nab-paclitaxel (GN). Preliminary median progression-free survival (PFS) was 9.6 months compared to historic median PFS of 5.5 months with GN. Analysis of paired pre- and on-treatment biopsy samples from demonstrated an increase in CD8+ T-cell density in tumors from all 11 patients treated with MCGN (p=0.007). Based on these promising results, the protocol was amended from a single arm expansion totaling 40 patients to a randomized phase 2 study. Methods: This is an open-label, multicenter, investigator-initiated phase 2 clinical trial. Patients are randomized 2:1 to receive MCGN or GNalone (N=108). The primary endpoint is progression free survival. The study has 80% power to detect an improvement in PFS from 6 to 9.2 months (HR 0.65) with a one-sided alpha of 0.20. One interim analysis for futility is planned when 50% of the PFS events are observed. Secondary objectives include response rate, disease control rate, duration of clinical benefit and overall survival. Patients will undergo optional paired biopsies which will be analyzed in conjunction with samples collected from the phase I pilot study. Exploratory studies include interrogation of the TME using quantitative multiplex immunofluorescence and single-cell RNA sequencing. The randomized phase 2 trial is open to enrollment and one patient has been randomized as of 1/29/2024. Clinical trial information: NCT04543071 .
A phase 3, randomized study of adjuvant rilvegostomig plus chemotherapy in resected biliary tract cancer: ARTEMIDE-Biliary01.
Fan, Jia , Ferrone, Cristina R. , Kayhanian, Hamzeh , Chen, Xin, Bai, Sally Yan, Drachsler, Moritz Wolfgang, Oh, Do‐Youn , Bekaii‐Saab, Tanios , Aldrighetti, Luca , Bridgewater, John , Harding, James J. , Ikeda, Masafumi , Knox, Jennifer J. , Wang, Julie

Mayo Clinic

Journal of Clinical Oncology | July 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS4199-TPS4199

10.1200/jco.2024.42.16_suppl.tps4199 Get It

TPS4199 Background: Biliary tract cancer (BTC) is a rare but aggressive heterogenous group of gastrointestinal cancers that arise from the intra- or extrahepatic bile ducts (cholangiocarcinoma [CCA]) or the gallbladder (GBC). In early-stage disease following curative resection, adjuvant chemotherapy with a fluoropyrimidine- or gemcitabine-based regimen is usually recommended, however, recurrence rates remain high (e.g. in the BILCAP study, 5-year recurrence-free survival with adjuvant capecitabine was 34%). Immunotherapy is efficacious as adjuvant therapy in other cancer types. Results from the TOPAZ-1 and KEYNOTE-966 studies support combining immunotherapy and chemotherapy in advanced BTC, including in locally advanced non-metastatic disease. Furthermore, dual inhibition of programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1) and the novel immune checkpoint, T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT), has shown promising results across multiple tumor types without major increases in high-grade toxicity compared with PD-1 or PD-L1 inhibition alone. Rilvegostomig is an anti-PD-1/-TIGIT bi-specific monoclonal antibody that appears active and well tolerated in non-small-cell lung cancer. ARTEMIDE-Biliary01 will investigate the efficacy of rilvegostomig plus standard of care adjuvant chemotherapy in patients with BTC after curative intent resection. Methods: ARTEMIDE-Biliary01 (NCT06109779) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global study to assess the efficacy and tolerability of rilvegostomig IV every three weeks versus placebo in combination with investigator's choice of chemotherapy (capecitabine, S-1 [tegafur/gimeracil/oteracil] or gemcitabine/cisplatin) as adjuvant treatment in patients with BTC after curative intent resection. This study will enroll approximately 750 adults with histologically confirmed adenocarcinoma of the biliary tract (intrahepatic or extrahepatic CCA or muscle-invasive GBC) after macroscopically complete resection (R0 or R1) and an ECOG PS of 0–1. Key exclusion criteria include locally advanced, unresectable, or metastatic disease at initial diagnosis and any anti-cancer therapy for BTC prior to surgery. The primary endpoint is recurrence-free survival, and the key secondary endpoint is overall survival. Additional endpoints include progression-free survival following recurrence, patient-reported tolerability, and safety. Enrollment has begun, and approximately 200 sites will be recruiting globally across Asia, Australia, Europe, North America, and South America. Clinical trial information: NCT06109779 .